Edition:
United States

DiaSorin SpA (DIAS.MI)

DIAS.MI on Milan Stock Exchange

69.80EUR
21 Feb 2018
Change (% chg)

€0.25 (+0.36%)
Prev Close
€69.55
Open
€69.85
Day's High
€69.90
Day's Low
€69.25
Volume
73,072
Avg. Vol
79,582
52-wk High
€82.10
52-wk Low
€57.25

Chart for

About

DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease,... (more)

Overall

Beta: 0.43
Market Cap(Mil.): €3,891.20
Shares Outstanding(Mil.): 55.95
Dividend: 0.80
Yield (%): 1.15

Financials

  Industry Sector
P/E (TTM): -- 50.44 16.73
EPS (TTM): -- -- --
ROI: -- 14.12 35.60
ROE: -- 16.71 17.23

BRIEF-DiaSorin Sees Tax Benefit In 2015-2017 Of 16-18 Mln Euros From Patent Box

* SIGNS AGREEMENT WITH TAX OFFICE REGARDING PATENT BOX TAX REGIME

Jan 30 2018

BRIEF-Qiagen, DiaSorin partner in automated tuberculosis detection

* SAYS ‍QIAGEN AND DIASORIN PARTNER TO OFFER FULLY AUTOMATED TUBERCULOSIS DETECTION WITH QUANTIFERON-TB GOLD PLUS AVAILABLE ON LIAISON ANALYZER SYSTEMS​

Jan 08 2018

BRIEF-Diasorin And Qiagen Partner To Offer Fully Automated Solution For Diagnosis Of Tuberculosis

* ANNOUNCES PARTNERSHIP WITH QIAGEN TO OFFER FULLY AUTOMATED SOLUTION FOR DIAGNOSIS OF TUBERCULOSIS

Jan 08 2018

BRIEF-Diasorin Receives CE Mark For A New Bordetella Molecular Diagnostic Test

* RECEIVES CE MARK FOR A NEW BORDETELLA MOLECULAR DIAGNOSTIC TEST Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Dec 12 2017

BRIEF-DiaSorin Q3 net profit up at EUR 29.3‍​ mln, confirms 2017 guidance

* Q3 NET REVENUE EUR ‍​149.4 MILLION VERSUS EUR 147.0 MILLION YEAR AGO

Nov 09 2017

BRIEF-Diasorin revises its FY 2019 guidance

* INCREASES ITS 2019 REVENUE GUIDANCE TO ABOUT EUR 775 MILLION FROM EUR 735 MILLION

Sep 29 2017

BRIEF-DiaSorin ‍completes acquisition of Elisa immunodiagnostic business portfolio​

* ‍COMPLETES ACQUISITION OF ELISA IMMUNODIAGNOSTIC BUSINESS PORTFOLIO AND ASSOCIATED ASSETS FROM SIEMENS HEALTHINEERS​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Sep 29 2017

BRIEF-DiaSorin ‍earns CE-mark extending sample claims for its Simplexa HSV 1&2 kit​

* ‍EARNS CE-MARK EXTENDING SAMPLE CLAIMS FOR DIASORIN MOLECULAR'S SIMPLEXA HSV 1 & 2 KIT​

Sep 21 2017

Earnings vs. Estimates